Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2012

View Archived Issues

NeoGenomics launches prognostic cancer test in U.S.

Discovery of a novel mineralocorticoid receptor antagonist

Proteome Sciences provides CKI-delta inhibitor portfolio update

Foundation Medicine and Clovis Oncology launch collaboration

Aquapharm discovers antibiotic against multidrug-resistant bacteria

Antisense products show promise in model of myotonic dystrophy

Fate Therapeutics divulges novel Wnt compositions

ACEA Biosciences presents new candidate cancer therapeutics

In vivo studies demonstrate neuroprotective effects of microRNA's silencing

Crystal Biopharmaceutical patents novel camptothecin derivatives

New anticancer microRNA prepared in the Netherlands

Ono Pharmaceutical announces highlights of second quarter 2012

Researchers at Lilly disclose novel kinase inhibitors

Shire reviews accomplishments for second quarter of 2012

Astellas files for approval of orally disintegrating tablet for IBS

NeurogesX provides update on next steps for NGX-1998

Trana identifies new target for development of antibiotics

Antibody targeting Wnt/beta-catenin pathway shows promising anticancer activity

Affinium completes enrollment in phase II trial of oral antibiotic for ABSSSI

New cancer vaccines designed by Oncbiomune

Mylan out-licenses Japanese rights to next-generation epinephrine product

Novel immune deficiency and immune dysregulation phenotype and related gene mutation identified

Recruitment complete in study of rheumatoid arthritis stem cell therapy

Achillion provides update on candidate drugs for genotype 1 HCV infection

AstraZeneca to halt development of CytoFab

OncoGenex kicks off enrollment in AFFINITY study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...